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Abstract Males with X-linked agammaglobulinaemia
(XLA) due to mutations in the Bruton tyrosine kinase
gene constitute the major group of congenital hypo-
gammaglobulinaemia with absence of peripheral B
cells. In these cases, blockages between the pro-B and
pre-B cell stage in the bone marrow are found. The
remaining male and female cases clinically similar to
XLA represent a genotypically heterogeneous group of
diseases. In these patients, various autosomal recessive
disorders have been identified such as mutations af-
fecting IGHM, CD79A, IGLL1 genes involved in the
composition of the pre-B cell receptor (pre-BCR) or
the BLNK gene implicated in pre-BCR signal trans-
duction. In this paper, we report on a young female
patient characterised by a severe non-XLA agamma-
globulinaemia that represents a new case of Igl defect.
We show that the B cell blockage at the pro-B to pre-
B cell transition is due to a large homologous deletion
in the IGH locus encompassing the IGHM gene
leading to the inability to form a functional pre-BCR.
The deletion extends from the beginning of the di-
versity (D) region to the IGHG2 gene, with all JH
segments and IGHM, IGHD, IGHG3 and IGHG1
genes missing. Conclusion: alteration in Igl expression
seems to be relatively frequent and could account for
most of the reported cases of autosomal recessive
agammaglobulinaemia.
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Introduction
Recurrent infections, mostly respiratory, with pyogenic
bacteria are the predominant manifestations of children
suffering antibody deficiencies. In some of these patients,
early B cell development in the bone marrow is arrested
and hypogammaglobulinaemia results from the absence
of peripheral B cells. In these cases, chronic diarrhoea
could also be observed and constitutes a serious clinical
problem. This occurs in X-linked agammaglobulinaemia
(XLA), also known as Bruton disease, characterised by
defects in the Bruton tyrosine kinase gene (BTK) [13,14]
that encodes the cytoplasmic tyrosine kinase btk, in-
volved in signal transduction. In these cases, B cell de-
velopment is blocked in the bone marrow at the pre-B
cell stage, resulting in the accumulation of CD34+
CD19+ pro-B cells and in the presence of variable
numbers of CD34-CD19+ pre-B cells. Females with a
phenotype indistinguishable from XLA have also
been described and Conley et al. [2] have estimated
that these immunodeficiencies represent 10% of patients
with congenital hypogammaglobulinaemia. The defects
behind such autosomal recessive disorders have been
recently identified and shown to affect predominantly
the pre-B cell receptor (pre-BCR), which is an absolute
prerequisite for pro-B to pre-B cell transition and to
allow further B cell differentiation [3,12]. This receptor,
expressed on pre-B cells is composed of the Igl, the YL
chain (made of k-like and VpreB) and the Iga/Igb
transducing complex [5]. For example, mutations
affecting IGHM [12,15], CD79A [10], IGLL1 [9] or
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BLNK that encodes a B cell linker protein essential for
Igl signal transduction [11], have been reported.
In this paper we describe a new case of autosomal
recessive agammaglobulinaemia due to a large deletion
of the immunoglobulin heavy chain locus (IGH),
including the IGHM gene, that results in the absence of
a functional pre-BCR.
Case report
The patient, a 35-month-old girl, was the second child of healthy
parents born in the same small village, near Braga, Portugal, who
were thought to be non-consanguineous (see below). She had a
healthy 6-year older brother. Apart from symmetrical intrauterine
growth retardation due to uteroplacental insufficiency, no other
significant abnormalities related to family history, pregnancy and
delivery were detected. An echocardiogram confirmed a congenital
cardiopathy, secundum ASD (atrium secundum, intra-auricular
communication) which resolved spontaneously without surgery. At
9 months of age she was referred to the Paediatric Gastroenterol-
ogy Department because of failure to thrive and chronic diarrhoea
during the previous month. Her weight was 5 640 g (P<3), her
height 60 cm (P<3) and her head circumference 40.8 cm (P<5).
Physical examination showed that she was not dehydrated, she had
no detectable tonsils and no palpable adenomegaly and revealed
that she had elongated fingers (data not shown). According to the
Kanawati-McLaren index (0.31), she had no clinical signs of mal-
nutrition.
A routine blood examination showed leucocyte and platelet
counts of 27500/mm3 and 345000/mm3, respectively, and haemo-
globin at 13.2 g/dl. Total protein was 5.2 g/dl and albumin 3.7 g/dl.
Blood, urine and stool cultures were sterile. TORCH serology and
sweat tests were negative. Search in stools for virus, parasites, re-
ducing sugar and fat was negative. Alpha-1 anti-trypsin in stools
was <1.7 mg/g dry weight (normal <5.0 mg/g). Histology of a
duodenal biopsy showed no histological changes but immunocy-
tochemistry revealed a complete absence of B cells and normal
numbers of T cells. The patient responds to BCG and oral polio-
myelitis vaccines without any complication.
Her peripheral blood immunological data, determined at 10
months of age, are presented in Table 1. A clear agammaglobuli-
naemia was evident with a serum IgG level of 5 mg/dl and unde-
tectable IgM and IgA. Lymphocyte phenotyping showed the
absence of circulating B cells (CD19 or CD20 positive cells), nor-
mal numbers of CD4 T lymphocytes and increased numbers and
proportions of NK and CD8 T cells, this latter population showing
increased expression of HLA-DR, CD45RO and CD95 activation
markers (data not shown).
Since the age of 10 months, she has been treated with intrave-
nous replacement immunoglobulin therapy (400 mg/kg every 3
weeks, with pre-administration levels of 300–500 mg/dl). During
the 25 months follow-up, two episodes of gastroenteritis, a viral
rhinitis and an ear infection were diagnosed, which, however, did
not require anti-microbial therapy.
The parents gave informed consent for this investigation.
Materials and methods
Immunoglobulin measurement and cell phenotyping
Serum immunoglobulin IgG, IgA, and IgM were determined by
rate nephelometry. Whole peripheral blood and bone marrow
mononuclear cells isolated by Ficoll-Hypaque gradient were used
for phenotyping. Cell surface antigens were stained with conjugated
anti-human monoclonal antibodies and were analysed by flow
cytometry. Bone marrow mononuclear cells were stained with
FITC-conjugated monoclonal antibodies against CD10, CD20,
CD34, CD3, CD4 or phycoerythrin-conjugated monoclonal anti-
bodies against CD19, CD8, CD16 and CD56, from Immunotech
(France). Phycoerythrin-conjugated anti-Igd and APC-conjugated
anti-CD19 were from Pharmingen (France). Biotin-conjugated
anti-human Igl chain from Southern Biotechnology (USA) was
revealed with PerCP-conjugated Streptavidin (Becton and Dickin-
son, USA). Peripheral blood B cells were stained with FITC-con-
jugated monoclonal antibodies against CD19, CD20, CD4, CD8,
phycoerythrin-conjugated monoclonal antibodies against CD8,
CD16, CD56, PE/Cy5-conjugated monoclonal antibodies against
CD3, from Immunotech (France) and from Dako, SA (Denmark),
and were haemolysed and fixed (T–prep, Beckman-Coulter) before
flow cytometric analysis.
RNA and reverse transcriptase polymerase chain reaction
Total RNA was extracted from total bone marrow cells using
TRIzol Reagent (Gibco BRL) as described by Chomczynski and
Sacchi [1]. RNA (2 lg) was reverse transcribed using the reverse
transcriptase Superscript II (Gibco BRL), 1 lg of random hexamer
(dN6), 1 mM dNTPs and the supplied buffer. For reverse tran-
scriptase-PCR, 1 ll of cDNA was amplified for 30 cycles of 30 s at
94C, 1 min at the appropriate temperature and 2 min at 72C with
a final 10 min extension at 72C, using Taq DNA polymerase
(BRL) and the primers already described [12].
DNA and DNA-polymerase chain reaction
Genomic DNA was extracted from peripheral blood mononuclear
cells with proteinase K, sodium dodecyl sulphate and phenol-
chloroform extractions. PCR was performed, as above, using
100 ng of DNA. For semi quantitative analysis, PCRs were carried
out during the exponential phase of the DNA amplification. In that
case, the exponential phase of each PCR was determined by titra-
tion of cycle numbers and by quantities of total DNA. PCR
products were analysed on 2% agarose gels and revealed by ethi-
dium bromide (BET) staining. Quantification was performed using
the MacBas software.
Results
Phenotypic analysis of bone marrow cells
Peripheral blood phenotype of the patient revealed a
pure B cell defect since a profound agammaglobulina-
emia with a total absence of peripheral B cells was
observed and since the levels and phenotype of T and
Table 1. Immunological data
Patient (aged
10 months)
Age-matched
controls
Lymphocyte count (103 cells/ll) 1.1 3–8
Serum immunoglobulins (mg/dl)
IgM <0.1 25–182
IgG 5 441–880
IgA <0.1 11–117
Blood B lymphocytes (%)
CD19 <0.01 19–31
CD20 <0.01 19–31
Blood T lymphocytes (%)
CD3 84 55–79
CD4+/CD3+ 46 35–59
CD8+/CD3+ 38 16–34
Blood NK lymphocytes (%)
CD3-/CD16+CD56+ 16 4–11
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NK cells did not indicate a T-B-combined immunode-
ficiency. Thus, we analysed bone marrow B cell sub-
populations. A bone marrow sample was obtained when
the patient (from now referred as the IglD patient, see
below) was 24 months old. Total CD19+ patient’s B
cells were diminished more than three-fold (13% versus
43% in age matched control) and the population of large
B cells, mainly corresponding to proliferating pre-B
cells, was nearly absent (Fig. 1A). Gated CD19+ cells
were completely negative for surface Igl expression
(Fig. 1B) and for Igd and CD40 expression (data not
shown), indicating a total absence of immature and
mature B cells in the patient’s bone marrow. In contrast,
CD34+ precursors and CD34+CD19+ pro-B cells
were within normal limits as compared to an age-mat-
ched control (Fig. 1C). Altogether these data indicate
that the patient suffered from an early bone marrow B
cell blockage, between pro-B and pre-B cell stages.
Molecular analysis
RT-PCR analysis was performed on total mononuclear
bone marrow cells for transcripts expressed during the
pro-B to pre-B cell transition, including k-like, VpreB,
Iga, Igb, and Blnk. The resulting PCR products were
directly sequenced and were normal (data not shown). In
contrast, no transcripts were detected for IgCl specific
amplification. This result was confirmed at the DNA
level since no amplification could be detected using the
lCH1 and lCH2 oligonucleotides (Table 2, Fig. 2) for
the patient’s DNA. These data indicate that a deletion
within the IGH locus, carried by both alleles, was re-
sponsible for the patient’s phenotype.
To analyse the extent of the DNA deletion, we per-
formed a detailed analysis of the IGH locus by PCR. By
using JH5-JH6 and dCH2-dCH3 primers, we showed
that the JH cluster and the IGHD gene respectively were
completely missing. Moreover, we mapped the 5’ end of
the deletion between the IGHD2–2 and the IGHD3–10
genes within the IGHD locus, since we could amplify the
IGHD2–2 and not the IGHD3–10 gene (Fig. 2). Using
cCH2 and cCH3 oligonucleotides that are common to
different IGHG gene sub-classes, we demonstrated that
some IGHG genes were present in the patient’s genome.
Fig. 1. FACS analysis of bone marrow B cell sub-populations for
the IglD patient and an age-matched control (Ctrl). A Bone
marrow mononuclear cells from IglD and an age-matched control
were stained with anti-CD19 monoclonal antibody and analysed by
flow cytometry. Fluorescence intensity of stained cells is presented
as a function of cell size (forward scatter). B Bone marrow
mononuclear cells were stained with anti-CD19 and anti-Igl
monoclonal antibodies and CD19+ cells, gated and analysed for
Igl chain expression. Solid and empty curves represent IglD patient
and age-matched control, respectively. C Bone marrow mononu-
clear cells were stained with anti-CD34 and anti-CD19 monoclonal
antibodies. Dot plots show precursor (CD34+), pro-B
(CD34+CD19+) and pre-B+immature+mature (CD34-
CD19+) bone marrow B cell sub-populations
Table 2. Oligonucleotide primers used for DNA-PCR amplification
Locus Form Primers used (5’ to 3’) Annealing
temperature (C)
Product
size (bp)
D 2-2 Sense GATATTGTAGTAGTACCAGCTGC 66 422
Antisense GTAGGATAGCGGCTGCTTCTC 66
D3-10 Sense GTATTACTATGGTTCGGGGAG 62 564
Antisense GAAATGACCCAGGAGAGGCTC 66
JH5-JH6 Sense GCCGTCTGCTTGCAGTTGGAC 68 593
Antisense CTACAGACACCGCTCCTGAGAC 70
lCH1-lCH2 Sense AGGGAGTGCATCCGCCCCAAC 68 647
Antisense CTTTGATGGTCAGTGTGCTGGTC 70
dCH2-dCH3 Sense GCAGTGCAGGACCTGTGGCTC 70 577
Antisense GCCAGACACCTCACACAGGAGC 72
cCH2-cCH3 Sense GGAGGTGCATAATGCCAAGACAAAG 74 360
Antisense TTGACCAGGCAGGTCAGGCTGAC 74
Sc1 Sense GCAGAGCATCACAACGTCAGC 66 261
Antisense GAGCTAGTCCTGCTCACCTTC 66
c2H-c2CH2 Sense GCGCAAATGTTGTGTCGAGT 60 175
Antisense CGGTCCTGCCACAGGTGG 62
VpreB Sense CTGAGATATTTCTCACAATCAGAC 66 284
Antisense TCTTCCATGACAGTCTCTCCAAG 68
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Using specific primers in the IGHG1 switch region (Sc1)
or in the hinge region of the IGHG2 gene (c2H and
c2CH2), we finally demonstrated that the 3’ end of the
DNA deletion was located between the IGHG1 and the
IGHG2 genes (Fig. 2). The size of the DNA deletion was
estimated to be between 165 to 265 kb [6].
Family studies
The PCR results obtained for the IglD patient suggested
the presence of a large homologous DNA deletion of
familial origin. A semi-quantitative PCR was performed
using VpreB and Igl specific primers on the DNA ex-
tracted from peripheral blood mononuclear cells of the
father, mother, brother and a healthy donor (Fig. 3A).
Since VPREB is a unique gene in the human genome [4]
it was used to quantify Igl PCR products. The results
clearly demonstrated that the DNA from both the father
and the mother contained only one copy of the func-
tional IGHM gene (Fig. 3B). In contrast, DNA of the
brother as well as control DNA contained two copies of
the IGHM allele (Fig. 3B). The patient’s brother was
therefore homozygous for the functional IGHM allele.
Discussion
Approximately 85% of patients with congenital hypo-
gammaglobulinaemia and absent peripheral B cells are
males with XLA due to mutations in the BTK gene. The
remaining 15% of cases, clinically identical to XLA, are
still a heterogeneous group. Some mutations have been
already identified, especially in components of the pre-
BCR, such as IGHM [12,15], IGLL1 [9], CD79A [10], or
BLNK [11] that result in impaired pre-B cell differenti-
ation. However, alteration in Igl expression seems to be
relatively frequent. For example, Yel et al. [15] described
three different mutations in the IGH locus. For one
consanguineous family, the affected patients had a DNA
deletion covering 75–100 kb that encompassed the di-
versity genes (DH), the JH cluster and the IGHM gene.
Fig. 2. Molecular analysis of the patient’s gene defect. Schematic
representation (top) of the human IGH locus and localisation of the
primers used for DNA amplification. Extent of the IglD patient
DNA deletion is shown. PCR amplification (bottom) of the IglD
patient DNA using the indicated oligonucleotides (see Table 2). 0,
C and P lanes correspond to PCR without DNA, control DNA and
IglD patient DNA, respectively. Amplified DNA products were
separated on 2% agarose gels and revealed by BET staining
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For another consanguineous family, the alteration cor-
responded to a homozygous single G to A base pair
substitution at the –1 position of the alternative splice
site used to produce the membrane form of the Igl
transcript. This mutation would inhibit the production
of the membrane Igl chain. It was also reported that a
boy, who did not suffer from a BTK alteration, had a
heterozygous alteration of the IGHM gene. In this case,
a single base pair substitution affecting an invariant
cysteine residue in the CH4 domain of the IGHM chain
for one allele, coupled to a large deletion of the IGH
locus on the other allele, was detected. We have also
reported the case of a girl, referred to as the Igl–/– pa-
tient [7,12], in whom we identified a cytosine insertion at
the beginning of the CH1 exon of the IGHM gene, re-
sulting in a stop codon at position 48, and in the absence
of Igl chain expression. The patient reported in this
paper, designated as the IglD case [8], with a large 165 to
265 kb homologous deletion of the IGH locus encom-
passing the IGHM gene, represents a new case of Igl
defect. Altogether we can conclude that Igl alterations
account for most of the reported cases of autosomal
recessive agammaglobulinemia. These observations also
emphasise the requirement of signalling via a functional
pre-BCR to ensure normal early B cell differentiation.
Moreover, the absence of Igl chains in Igl–/– and IglD
patients, has provided an opportunity to elucidate the
role of Igl in selecting the antibody repertoire in humans
[8].
Along with a better understanding of B cell biology
and its developmental defects, identification of such
genetic alterations may open the way for new clinical
treatments, including somatic gene therapy. Moreover it
provides a basis for a more accurate diagnosis, com-
prising the identification of carrier status, prenatal test-
ing and counselling.
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